Building on our knowledge of the medicinal chemistry, biological activity and mechanism of action of NLRP3 inflammasome inhibitors, NodThera are creating a next-generation pipeline of small molecules that are optimized for potency, PK and tissue penetration. NodThera are also optimizing for structural attributes that enable individual candidate molecules to be targeted to specific disease indications.